版本:
中国

BRIEF-Fibrocell receives rare pediatric disease designation from FDA for FCX-013

June 12 Fibrocell Science Inc

* Fibrocell receives rare pediatric disease designation from FDA for FCX-013 for treatment of localized scleroderma

* Fibrocell Science Inc says expects to submit an investigational new drug application (IND) to FDA in Q4 of 2017 for FCX-013

* Fibrocell Science Inc says FCX-013 and FCX-007 are being developed in collaboration with intrexon Source text for Eikon: Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐